ClinicalTrials.gg
RecruitingNCT07365930NISTIPSUpdated Feb 5, 2026

NIS on the Benefits of TIPS in Patients With HCC Receiving Atezo+Bev in 1st-Line Therapy

An observational study in Hepatocellular Carcinoma (HCC), sponsored by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-05.

Sponsored by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Observational

How we know · 2 judgments

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
350
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 149 studies in Carcinoma, Hepatocellular with a site in Germany — 23 open to participants now, 38 under way, 9 of them phase 3. Carcinoma, Hepatocellular · Germany.

Planned enrollment
10th of 25
350 · median 250
Started
2025
with 6 others
Observational
25 of 149
5 open now
Primary completion
2031-12
later than 36 of 37 live
Registered
146th of 149
by date
Lead sponsor
8 of 149
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Among the 149 studies in Carcinoma, Hepatocellular with a site in Germany, this one is the 10th largest by planned enrollment of the 25 observational ones that give a count, is one of 7 that started in 2025, is one of 25 observational ones, reaches primary completion later than 36 of the 37 other live ones, and was the 146th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

23 of the 149 studies in Carcinoma, Hepatocellular with a site in Germany are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 149 studies in Carcinoma, Hepatocellular with a site in Germany, or all of them as a file.
02

Study summary

The NISTIPS TRITICC-4 study is a prospective, multicentre, non-interventional cohort study to analyze the effectiveness of transjugular intrahepatic portosystemic shunting (TIPS) in patients with Hepatocellular carcinoma (HCC) receiving atezolizumab plus bevacizumab as first-line treatment. It will further characterize the effectiveness of atezolizumab and bevacizumab therapy, investigate post-market safety and evaluate health-related quality in HCC patient cohorts with or without TIPS in a real-world setting.

Read the detailed description

While TIPS effectively treats CSPH in cirrhosis, its role in HCC patients receiving systemic therapy remains unclear. The NISTIPS TRITICC-4 study will investigate whether TIPS in patients receiving atezo+bev reduces portal hypertension-related complications and improves therapy outcomes. We hypothesize that TIPS is feasible in non-resectable HCC, lowers the risk of hepatic decompensation, and improves survival and treatment effectiveness by preserving liver function. Furthermore, an observational cohort study like NISTIPS TRITICC-4 offers an opportunity to evaluate the effectiveness, safety and tolerability of atezo+bev treatment with or without TIPS in a more heterogeneous patient population, by capturing data on treatment outcomes, quality of life, and safety in daily clinical practice. Moreover, it helps to identify patient subgroups, which may derive benefits or experience specific risks, helping to optimize personalized treatment strategies.

The NISTIPS TRITICC-4 study is a prospective, multicentre, cohort study with associated accompanying research including archival tissue sample collection, which enrolls 350 patients in Germany of both sexes and ages over 18 years. Eligible patients are diagnosed with locally advanced or metastatic and/or unresectable Hepatocellular Carcinoma (HCC) in 1st line therapy setting without (Analysis Cohort 1) or with (Analysis Cohort 2) TIPS receiving atezolizumab + bevacizumab according to the market authorization.

03

Conditions studied

  • Hepatocellular Carcinoma (HCC)

Keywords

  • HCC
  • TIPS
  • Tecentriq
  • Avastin
  • transjugular intrahepatic portosystemic shunting
  • Hepatocellular carcinoma
  • observational study
  • non-interventional study
  • Atezolizumab
  • Bevacizumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The NISTIPS TRITICC-4 study enrolls participants in Germany of both sexes and ages over 18 years. Eligible patients are diagnosed with locally advanced or metastatic and/or unresectable Hepatocellular Carcinoma (HCC) in 1st line therapy setting without (Analysis Cohort 1) or with (Analysis Cohort 2) TIPS.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The patient has a confirmed, locally advanced or and/or unresectable HCC with:

    1. the presence of liver cirrhosis (cirrhosis confirmed by histology or liver stiffness or with unequivocal signs in ultrasound, endoscopy, and/or blood tests),
    2. a disease that is not amenable to curative surgical and/or locoregional therapies, or a progressive disease after surgical and /or locoregional therapies,
  2. A decision for treatment with atezolizumab + bevacizumab according to the market authorization with or without TIPS has been made before enrolling into the study by the treating physician.

NOTE: Patients who have already received 1-2 cycles of atezo+bev therapy are eligible for enrollment into the NISTIPS TRITICC-4 study, when the prescription of the medicine or other therapeutic strategies are clearly separated from the decision to include the patient in the study.

Exclusion criteria

Exclusion Criteria:

  1. The patient has not provided signed .
  2. The patient is under 18 years of age at the time of giving signed informed consent.
  3. The patient is unable to understand all implications of study participation.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
350 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • HCC patients in atezo+bev treatment without TIPS

    Out of 350 HCC patients 168 patients with histologically confirmed, locally advanced or metastatic and/or unresectable liver cancer, without prior transjugular intrahepatic portosystemic shunting and receiving atezolizumab + bevacizumab treatment, will be assigned to analysis cohort 1: HCC patients in atezo+bev treatment without TIPS

  • HCC patients in atezo+bev treatment with TIPS

    Out of 350 HCC patients 182 patients with histologically confirmed, locally advanced or metastatic and/or unresectable liver cancer, with prior transjugular intrahepatic portosystemic shunting and receiving atezolizumab + bevacizumab treatment, will be assigned to analysis cohort 1: HCC patients in atezo+bev treatment with TIPS

This study also gives AtezolizumabStudies of AtezolizumabAtezolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Time to deterioration of liver function (TTDL)

    Time to deterioration of liver function (TTDL) is used as outcome measure to analyze the effectiveness of transjugular intrahepatic portosystemic shunting (TIPS) in patients with Hepatocellular carcinoma (HCC) receiving atezolizumab plus bevacizumab as first-line treatment in a real-world scenario. Liver function deterioration is registered if any of the following criteria was met for more than 4 weeks (\>28 days in a row): * Total bilirubin \> 2.0 x ULN OR \> 2.0 x baseline if baseline was abnormal * Alanine aminotransferase (ALT) AND aspartate aminotransferase (AST) \> 5x ULN OR \> 5.0 x baseline if baseline was abnormal * Alkaline phosphatase \>2.5x ULN OR \> 2.5 x baseline (if baseline was abnormal)

    Time frame: up to 72 months

Secondary outcomes

  1. Overall survival (OS)

    Overall survival (OS) is used as measurement to further characterize the effectiveness of atezolizumab and bevacizumab therapy in real-world HCC patient cohorts with or without TIPS.

    Time frame: up to 72 months

  2. Time on treatment (ToT)

    Time on treatment (ToT), defined as duration from the first day of atezo+bev therapy to the day of the last dose of atezo+bev therapy

    Time frame: up to 72 months

  3. Prevalence of bleeding adverse events

    Prevalence of bleeding adverse events post-administration of atezo+bev treatment

    Time frame: up to 72 months

  4. Overall Response Rate (ORR)

    Overall Response Rate (ORR) defined as the proportion of patients with a best overall response of complete response (CR) or partial response (PR), as assessed by the investigator according to local protocol.

    Time frame: up to 72 months

  5. Time to New Extrahepatic Lesions or death due to any cause (TTNEL)

    Time to New Extrahepatic Lesions or death due to any cause (TTNEL) after initiation of atezo+bev treatment

    Time frame: up to 72 months

  6. Post-market safety of atezolizumab plus bevacizumab

    To investigate post-market safety of the authorized treatment with atezolizumab plus bevacizumab in HCC patient cohorts with or without TIPS, type, frequency, causality and severity of adverse events with severity according to NCI CTCAE v5.0 including the rate of TIPS-related complications will be analyzed.

    Time frame: up to 72 months

  7. Proportion of patients with improved, maintained, or worsened Health-Related Quality of Life (HR-QoL) according to EORTC QLQ-C30 and QLQ-HCC18 assessment

    Proportion of patients with improved, maintained, or worsened Health-Related Quality of Life (HR-QoL) scores with a ≥ 10-point change considered clinically meaningful in HR-QoL scores derived from EORTC QLQ-C30 and QLQ-HCC18 assessment is the used measurement to evaluate health-related quality of life in real-world HCC patient cohorts receiving atezolizumab plus bevacizumab as first-line treatment with or without TIPS.

    Time frame: up to 72 months

  8. Time to HR-QoL Deterioration (HR-QoL TTD) derived from EORTC QLQ-C30 and QLQ-HCC18 assessment

    Time to HR-QoL Deterioration (HR-QoL TTD), measured from study enrolment to the first ≥10 points decrease of HR-QoL score compared to baseline HR-QoL score with HR-QoL scores derived from EORTC QLQ-C30 and QLQ-HCC18 assessment, is the used measurement to evaluate health-related quality of life in real-world HCC patient cohorts receiving atezolizumab plus bevacizumab as first-line treatment with or without TIPS.

    Time frame: up to 72 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — It is not yet known if there will be a plan to make IPD available.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2031, 72 months after the start.

Of 303 non-industry observational studies under Carcinoma, Hepatocellular, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 114. This study's planned 72 months is above that.

Counting every sponsor, half of 352 studies reached it within 51 months; a quarter within 32 and three quarters within 108.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2025
First posted
Jan 26, 2026
StartActual
Dec 17, 2025
Primary completionEst.
Dec 17, 2031
CompletionEst.
Dec 17, 2031
Last update
Feb 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07365930
Lead sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Collaborators
Roche Pharma AG, Heinrich-Heine University, Duesseldorf
Responsible party
Sponsor
First posted
Jan 26, 2026
Start date
Dec 17, 2025
Primary completion
Dec 17, 2031 (estimated)
Completion
Dec 17, 2031 (estimated)
Last update
Feb 5, 2026

Study contacts

Christoph Roderburg, Professor
Contact
christoph.roderburg@med.uni-duesseldorf.de
04969589978719
Bianca Zaepf
Contact
zaepf.bianca@ikf-khnw.de
04969589978778
Christoph Roderburg, Professor
principal investigator · Heinrich Heine University of Duesseldorf, University Hospital of Duesseldorf

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion